CEPH - CEPHALON | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
CEPH - CEPHALON

An SI Board Since December 2001

Posts	SubjectMarks	Bans	Symbol
109	11	0	CEPH

Emcee: Jon Khymn	Type: Moderated

Introduction Market Data Compact

Cephalon, Inc. is an international biopharmaceutical company focused on the discovery, development and marketing of products to treat sleep disorders, neurological disorders, cancer and pain.

In the United States, the Company markets three products, Provigil (modafinil) Tablets [C-IV] for treating excessive daytime sleepiness associated with narcolepsy, Actiq (oral transmucosal fentanyl citrate) [C-II] for the management of cancer pain in opioid tolerant patients, and Gabitril (tiagabine hydrochloride) for the treatment of partial seizures associated with epilepsy.

In the United Kingdom, the Company markets Provigil and five other products, including Tegretol (carbamazepine), a treatment for epilepsy, and Ritalin (methylphenidate), a treatment for attention deficit hyperactivity disorder (ADHD).

The Company also markets other products in France, Germany, Austria and Switzerland.

cephalon.com

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
109	The question in my case is will it be considered off-label use if it's presc	idos	-	4/13/2009
108	Will it be considered off-label use if it's prescribed for travel in a prope	DewDiligence_on_SI	-	4/7/2009
107	Nuvigil proved effective in treating jet lag symptoms in phase III trial: thest	idos	-	4/7/2009
106	Cephalon in the anti TNF antibody arena - It launched takeover bid for Australia	idos	-	3/1/2009
105	CEPH is interested in a humanized IL-5 antibody: <b>Cephalon gets option	idos	-	1/14/2009
104	Treanda got a label expansion into refractory indolent NHL. thestreet.com	idos	-	11/29/2008
103	Didn't beat but raised: <b>Cephalon Boosts Full-Year Forecast</b&g	idos	-	10/29/2008
102	That was quick - U.S. patent no. 7,387,793 was issued to Eurand, the developer o	idos	-	10/2/2008
101	An FDA panel voted 17-3 against expanding Fentora’s label to include non-cancer	idos	-	5/7/2008
100	Watson has filed an ANDA to sell a generic version of Fentora. biz.yahoo.com	idos	-	4/24/2008
99	Merrill Cephalon, Inc. (CEPH, US$65.89, C-1-9) Amrix could drive CEPH higher. W	tom pope	-	3/27/2008
98	And as such they have priced Treanda's $1,800 per 100mg vial.	idos	-	3/27/2008
97	Finally, they're a bona fide oncology company.	DewDiligence_on_SI	-	3/20/2008
96	FDA has approved Treanda for the 1st-line treatment of chronic lymphocytic leuke	idos	-	3/20/2008
95	Lawsuit Claims Cephalon Delayed Sale of Generics By AVERY JOHNSON and JOHN R.	Doc Bones	-	2/14/2008
94	Cephalon Drug Is Tied To Several Deaths Off-Label Marketing Of Cancer Painkille	Doc Bones	-	9/14/2007
93	Binary event? Merrill: Company Updates Cephalon, Inc. (CEPH, US$67.88, C-2-9) S	tom pope	-	3/15/2007
92	Arsenic Drug Helps Treat Rare Cancer [WSJ] By JENNIFER CORBETT DOOREN January	Doc Bones	-	1/25/2007
91	Cephalon Used Improper Tactics To Sell Drug, Probe Finds [WSJ] By JOHN CARREYRO	Doc Bones	-	11/21/2006
90	Merrill: Cephalon, Inc. (CEPH; $54.65; C-2-9) Maintain Neutral. Scenario Analys	tom pope	-	6/21/2006
89	Cephalon Receives Approvable Letter for NUVIGIL This is an unusual outcome in t	DewDiligence_on_SI	-	5/2/2006
88	Forbes mag is touting the stock with talk of a short squeeze. I guess I just don	Cosmo Daisey	-	5/1/2006
87	Sparlon musings: tinyurl.com I’m not fully convinced that CEPH will bother wit	DewDiligence_on_SI	-	3/23/2006
86	Geeze, I made that bottle of Provigil last for a year and a half! Needless to sa	Mike McFarland	-	1/8/2006
85	I think the news out today about a Connecticut AG probe is very bearish and the	nicewatch	-	11/9/2004

Go to reply# or date (mm/dd/yy):